AU Patent

AU2018203175B2 — Sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate

Assigned to Gilead Sciences Inc · Expires 2020-01-02 · 6y expired

What this patent protects

rbr\Interwovn\NRPortbl\DCC\RBR\16922374_l.docx-7/05/2018 ABSTRACT The present invention relates to sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6 trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5 methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-8-olateFormI. WO 2015/196…

USPTO Abstract

rbr\Interwovn\NRPortbl\DCC\RBR\16922374_l.docx-7/05/2018 ABSTRACT The present invention relates to sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6 trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5 methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-8-olateFormI. WO 2015/196116 PCT/US2015/036757 S700 -~00 100 5 10 15 20 25 30 35 40 2ThetaQ Fiue1 1/7

Drugs covered by this patent

Patent Metadata

Patent number
AU2018203175B2
Jurisdiction
AU
Classification
—
Expires
2020-01-02
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.